Correlation Between Champions Oncology and Erytech Pharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Champions Oncology and Erytech Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Champions Oncology and Erytech Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Champions Oncology and Erytech Pharma SA, you can compare the effects of market volatilities on Champions Oncology and Erytech Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Champions Oncology with a short position of Erytech Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Champions Oncology and Erytech Pharma.

Diversification Opportunities for Champions Oncology and Erytech Pharma

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Champions and Erytech is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Champions Oncology and Erytech Pharma SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Erytech Pharma SA and Champions Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Champions Oncology are associated (or correlated) with Erytech Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Erytech Pharma SA has no effect on the direction of Champions Oncology i.e., Champions Oncology and Erytech Pharma go up and down completely randomly.

Pair Corralation between Champions Oncology and Erytech Pharma

If you would invest  862.00  in Champions Oncology on December 30, 2024 and sell it today you would earn a total of  49.00  from holding Champions Oncology or generate 5.68% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy0.0%
ValuesDaily Returns

Champions Oncology  vs.  Erytech Pharma SA

 Performance 
       Timeline  
Champions Oncology 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Champions Oncology are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating fundamental drivers, Champions Oncology reported solid returns over the last few months and may actually be approaching a breakup point.
Erytech Pharma SA 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Erytech Pharma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Erytech Pharma is not utilizing all of its potentials. The newest stock price agitation, may contribute to short-term losses for the retail investors.

Champions Oncology and Erytech Pharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Champions Oncology and Erytech Pharma

The main advantage of trading using opposite Champions Oncology and Erytech Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Champions Oncology position performs unexpectedly, Erytech Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Erytech Pharma will offset losses from the drop in Erytech Pharma's long position.
The idea behind Champions Oncology and Erytech Pharma SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Complementary Tools

Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Transaction History
View history of all your transactions and understand their impact on performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum